Location:
Hyatt Regency Denver at the Colorado Convention Center
650 15th St
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room:
Capitol Ballroom 4-7 (Fourth Floor)
Schedule (MST):
11:45 AM – 12:15 PM – Registration and Lunch Buffet
12:15 PM – 1:45 PM – Educational Program
There is no registration fee for these events. However, preregistration is required as seating is limited.
Faculty:
Emily Olson, APRN, CNP, MSN
Instructor in Oncology
Mayo Clinic, Rochester
Division of Medical Oncology
Rochester, Minnesota
Elizabeth A O’Reilly, RN, NP, MSN, MPH
Nurse Practitioner
Breast Oncology
Susan F Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Boston, Massachusetts
Joyce O’Shaughnessy, MD
Chair, Breast Cancer Research Program
Baylor Charles A Sammons Cancer Center
Texas Oncology
US Oncology
Dallas, Texas
Denise A Yardley, MD
Senior Investigator, Breast Cancer Research
Sarah Cannon Research Institute
Tennessee Oncology PLLC
Nashville, Tennessee
Moderator:
Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech BioOncology, Lilly, Novartis and Puma Biotechnology Inc (via educational grants) during the Oncology Nursing Society’s (ONS) 42nd Annual Congress, May 3-7, 2017 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
MODULE 1: HER2-Positive Breast Cancer (BC)
DISCUSSION TOPICS
- Rationale for administering neoadjuvant systemic therapy (NST)
- Importance of age, nodal status and planned surgical approach in the use of NST for patients with HER2-positive BC
- FDA indication for pertuzumab as a component of NST; selection of a chemotherapy partner
- Monitoring patients for cardiac side effects during adjuvant anti-HER2 therapy; care considerations for patients receiving anthracycline versus nonanthracycline regimens
- Potential implications of the positive Phase III APHINITY trial results for the use of pertuzumab as a component of adjuvant therapy for patients with HER2-positive early BC
- Available data with and potential clinical role of neratinib as extended adjuvant therapy
- Common side effects observed with neratinib; potential strategies to mitigate associated gastrointestinal toxicity
- Ongoing trials evaluating novel anti-HER2 approaches in early disease settings
- Clinical factors influencing the sequencing of anti-HER2 agents in the metastatic setting
- Available data with and current clinical role of combined endocrine and anti-HER2 blockade for patients with ER-positive, HER2-positive metastatic BC
- Ongoing trials evaluating novel agents and strategies for patients with HER2-positive BC
MODULE 2: ER-Positive, HER2-Negative BC
DISCUSSION TOPICS
- Use of genomic assays to guide decision-making on the selection and duration of treatment in the neoadjuvant and adjuvant settings
- Clinical factors influencing the use of extended adjuvant endocrine therapy
- Optimizing first-line systemic therapy for patients with metastatic ER-positive BC; impact of prior hormonal therapy, symptomatology, performance status and disease-free interval
- Biologic rationale for combining CDK4/6 inhibitors with endocrine therapy
- Similarities and differences among palbociclib, ribociclib and abemaciclib
- Available Phase III data with and approved indications for palbociclib and ribociclib
- Incidence and management of common toxicities associated with CDK4/6 inhibitors
- Emerging Phase III efficacy and safety findings with abemaciclib in ER-positive metastatic BC; potential clinical role
- Incorporating everolimus into the treatment algorithm for patients with ER-positive metastatic BC
- Prevention and management of everolimus-associated mucositis/stomatitis
- Clinical factors influencing the decision to transition from endocrine treatment to chemotherapy for patients with ER-positive metastatic BC
MODULE 3: Triple-Negative BC (TNBC)
DISCUSSION TOPICS
- Clinical factors influencing the decision to administer NST to patients with TNBC
- Role of platinum-based neoadjuvant chemotherapy
- Sequencing therapeutic agents for patients with metastatic TNBC
- Mechanism of action of eribulin; assessment and mitigation of neuropathic effects
- Indications for BRCA mutation testing in patients with BC; implications of a BRCA1/2 germline mutation for prognosis and current therapeutic selection
- Biologic rationale for the evaluation of PARP inhibitors in patients with BRCA1/2 germline mutations
- Emerging data from the Phase III OLYMPIAD trial comparing olaparib to chemotherapy in the patients with HER2-negative metastatic BC harboring germline BRCA1/2 mutations; potential role of olaparib in clinical practice
- Ongoing clinical trials of PARP inhibitors (niraparib, veliparib, et cetera) in patients with early and advanced BC
- Novel strategies and approaches in TNBC:
- – Androgen receptor assays and the use of antiandrogens (eg, enzalutamide, abiraterone)
- – Available data with anti-PD-1/PD-L1 antibodies
- Use of next-generation sequencing to select patients with TNBC for clinical trial participation
Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer (BC).
Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:
- Apply existing and emerging research data to the diagnostic, therapeutic and supportive care of patients with early and advanced BC.
- Describe the influence of tumor phenotypes and/or molecular profiling assays in tailoring systemic treatment decisions for patients with early and advanced BC.
- Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of BC, including endocrine agents, chemotherapy regimens and biologic treatments.
- Develop a plan to manage the side effects associated with commonly employed systemic therapies to support quality of life and continuation of treatment.
- Assess emerging research on the safety and efficacy of novel agents under development in preparation for the potential availability of these therapies.
- Recall ongoing trials of other investigational approaches and agents in BC, and refer patients and obtain consent for study participation.
Accreditation Statements:
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity. Your certificate will be mailed to you within 4 to 6 weeks. International attendees, please note: In order for a certificate of completion to be issued, you must provide a valid email address.
ONCC/ILNA Certification Information:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2017/ILNA
Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.
Content Validation and Disclosures:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
Research To Practice staff and external reviewers — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
Supporters:
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech BioOncology, Lilly, Novartis and Puma Biotechnology Inc.
Hyatt Regency Denver at the Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room:
Capitol Ballroom 4-7 (Fourth Floor)
The Hyatt Regency Denver at the Colorado Convention Center is the host hotel for the 2017 ONS Annual Congress.
Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 3 — Breast Cancer. Onsite registration will be open starting at 11:45 AM (MST) on Thursday, May 4th.
If you are interested in standing by for seating (day of the program), please visit our registration desk located outside Capitol Ballroom 4-7 on the fourth floor of the Hyatt Regency Denver hotel at the Colorado Convention Center (650 15th St, Denver, CO 80202). You may arrive up to 45 minutes before the program start time and receive a standby ticket.
If seats become available for the program, we will accept standby registration on a first come, first served basis. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.
|
